Biotech’s key fourth-quarter data
Deciphera, Allakos and Uniqure are all set for important data disclosures.
Bayer beefs up discovery work with Vividion buyout
Growing interest in protein degradation helps explain why Bayer had to pay $1.5bn to corner the private group.
Who will follow Curis’s clinical validation?
As Curis clinically backs a novel oncology mechanism, several companies might review their own similarly acting projects.
